Avastin Articles
FDA clears new use for Roche's Avastin and Novartis' Exjade
25 January 2013
San Antonio breast cancer meeting highlights
10 December 2012
Fujifilm JV plans bevacizumab biosimilar; Fujifilm Diosynth Bio alliance with Piramal for ADCs
25 October 2012
New Zealand's PHARMAC decisions on Roche products
11 October 2012
Chugai files of Japanese approval of Avastin for ovarian cancer
11 October 2012
Chugai pushed into filing for Avastin glioblastoma indication in Japan
21 September 2012
NICE says Roche's Avastin in breast cancer does not provide enough benefit to justify its cost
21 August 2012
Pfizer says Torisel combo fails in Ph III for kidney cancer
13 August 2012
Trial and uptake of Regeneron's Eylea continues to rise among US retinal specialists; report
24 July 2012
SHA to fund Roche breast cancer drug Avastin in London
12 April 2012
Reimbursement and/or budget-related factors restrict use of angiogenesis inhibitor in Brazil and Mexico; Study
28 March 2012
Counterfeit Avastin found in USA by FDA
16 February 2012
Roche unit in partial patent deal with Regeneron over Eylea; new indication for Avastin
4 January 2012
Roche offers Germany a pay-for-performance deal on Avastin
31 October 2011
UK’s NICE negative draft guidance for metastatic colorectal cancer drugs Erbitux, Avastin and Vectibix
6 September 2011
US FDA advisory panel nixes Roche’s Avastin for breast cancer; but good news on Lucentis in DME
30 June 2011
Regeneron/Sanofi colorectal cancer drug Zaltrap will see peak-year sales of up to $250 million
13 May 2011
EMA’s CHMP advisory unit decisions include good news for Lilly, Bristol-Myers, Boehringer and Roche
18 April 2011
European Commission backs Roche’s Avastin/paclitaxel combo for metastatic breast cancer
4 March 2011
US FDA allows Genentech/Roche to present case for Avastin in metastatic breast cancer
25 February 2011
UK’s NICE backs NHS use of GlaxoSmithKline’s kidney cancer drug Votrient but again turns down Roche’s Avastin for breast cancer
24 February 2011
Roche/Genentech appeal FDA decision on Avastin for breast cancer; positive results with melanoma drug
19 January 2011
US FDA to halt breast cancer use for Roche’s Avastin, but EMA says it’s OK in combo with paclitaxel; no immediate somatropin concerns
17 December 2010
More NICE rejections, for Roche’s Avastin and Herceptin and GlaxoSmithKline’s Tyverb
15 December 2010
UK’s NICE again rejects Roche top selling cancer drug Avastin for treating metastatic colorectal cancer
15 November 2010
AstraZeneca prostate cancer drug fails in Phase III trial
28 September 2010
Positive CHMP opinions for AstraZeneca and Novartis, but suspension of Octapharma’s Octagam called for; Roche Avastin review
26 September 2010
Roche reports fatal Actemra allergic reaction to Health Canada; sees US delay for Avastin indication, as drug fails to met endpoints in AVANT study
20 September 2010
PDL BioPharma sues Roche’s Genentech over royalties
2 September 2010
Big blow for Roche, as US FDA advisory panel votes to withdraw Avastin approval for breast cancer treatment
21 July 2010
US FDA Advisory Panel likely to focus on increased death risk associated with Roche’s Avastin, says Nomura
14 July 2010
ASCO highlights include cancer drug news from Pfizer, Roche, Sanofi, Merck KGaA, Novartis and Eisai
7 June 2010
Leading 20 cancer drugs to generates sales of $1 billion in Australia by 2018; says Datamonitor study
14 March 2010
Mixed fortunes for Roche’s Avastin; Xeloda recommended by EU
26 February 2010
Roche 2009 figures miss targets, hit by Genentech buy costs and slowing sales of some cancer drugs
3 February 2010
Idera gets $4.3 million clinical milestone under its cancer drug deal with Merck KGaA
20 January 2010
US FDA clears restart of Roche Ph III Avastin trials; other strong data presented at San Antonio meeting
14 December 2009
NICE rejects Roche’s bowel cancer drug Avastin for a second time
27 November 2009
Meeting highlights from Europe’s CHMP November 16-19, 2009
23 November 2009
Targeted agents will drive gastric cancer drug market to nearly $1.5 billion in 2018
5 November 2009
US FDA clears two indications for Boehringer Ingelheim’s telmisartan and GSK’s Votrient for renal cancer
20 October 2009
Roche nine-month 2009 sales boosted by strong Tamiflu showing
15 October 2009
Roche’s Avastin could play an important role for patients with the most aggressive form of brain cancer
22 September 2009
PDL expects 18% rise in 2nd-qtr revenues
9 June 2009
Stock Commentary - New York week to June 1, 2009
4 June 2009
Pfizer halts Sutent Ph III breast cancer study
3 June 2009
Avastin boosts PFS 36% in HER2-negative patients
1 June 2009
Stock Commentary - Europe - week to may 11, 2009
14 May 2009
PDL BioPharma swings to profit on cost-cuts
11 May 2009
Stock Commentary - Europe - week to April 27, 2009
30 April 2009
NICE's "bizarre" decision
29 April 2009
Japan stock market week to April 27, 2009
28 April 2009
"Perverse" NICE again says "No" to new drugs
28 April 2009
SCLC drug market wil more than double to $648M in 2017
14 April 2009
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
